Prioritising domains of glucocorticoid therapy to measure in trials: Results from a modified delphi exercise from the OMERACT glucocorticoid impact working group
Authors' conclusion
The 10 domains identified through this exercise informed the proposed core domain set of GC effects to be considered for use in future clinical trials involving GCs.
Study context
- Population
- Patients and healthcare professionals rating candidate domains of GC adverse effects for a core outcome set (OMERACT GC Impact working group)
- Participants
- 363 patients
- Comparison
- Patients vs Healthcare professionals
- Patientsn = 295
- Healthcare professionalsn = 68
- Outcome
- Domains deemed critical to include by at least 70% in both groups after three Delphi rounds, plus domains selected by more than 70% of all participants in a final survey
Methodological detailsmodified Delphi, three rounds, Core domain set endorsed at the OMERACT 2020 virtual workshop
- Modified Delphi
- Three rounds
- Core domain set endorsed at the OMERACT 2020 virtual workshop
Recommendations
As reported in the abstract
Final list of potential core domains
- 10 domains: bone fragility, diabetes, eye problems and/or changes in vision, high blood pressure, infection, osteonecrosis, mood disturbance, fatigue, sleep disturbance, weight
Original publication
Prioritising domains of glucocorticoid therapy to measure in trials: Results from a modified delphi exercise from the OMERACT glucocorticoid impact working group. Semin Arthritis Rheum. Published 4 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →